Log in to your Inderes Free account to see all free content on this page.

Lipigon Pharmaceuticals

Less than 1K followers

Overview

Ownership

Investor consensus

All

Press releases

ShowingAll content types

Regulatory press release12/3/2025, 5:55 PM

Lipigon Pharmaceuticals presents top-line data from the Phase II clinical trial of Lipisense in patients with elevated blood lipid levels

Lipigon Pharmaceuticals

Press release11/21/2025, 11:19 AM

Redeye: Lipigon (Q3 Review) - Topline Before Year-End

Lipigon Pharmaceuticals

Press release10/14/2025, 8:58 PM

Lipigon Pharmaceuticals reports last patient visit in the three-month follow-up of its Phase II clinical study with Lipisense

Lipigon Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release8/26/2025, 12:28 PM

Redeye: Lipigon Q2 2025 - Last Patient In

Lipigon Pharmaceuticals

Regulatory press release7/6/2025, 7:03 AM

Lipigon Pharmaceuticals Enrolls Last Patient in Phase II Study with Lipisense®

Lipigon Pharmaceuticals

Press release5/27/2025, 6:36 AM

Redeye: Lipigon Q1 2025 - 64.5% Subscription Rate in the Rights Issue

Lipigon Pharmaceuticals

Press release3/31/2025, 6:25 AM

Redeye: Lipigon Q4 2024 - Rights issue funds 2025

Lipigon Pharmaceuticals

Regulatory press release3/20/2025, 11:15 AM

Lipigon Pharmaceuticals' commercial partner announces positive results from Phase I clinical trial with Lipisense

Lipigon Pharmaceuticals

Press release11/21/2024, 1:12 PM

Redeye: Lipigon Q3 2024 - First Patient Recruited

Lipigon Pharmaceuticals

Regulatory press release11/21/2024, 9:00 AM

Första patienten doserad i Lipigon Pharmaceuticals kliniska fas II-studie med Lipisense®

Lipigon Pharmaceuticals

Press release9/18/2024, 10:51 AM

Lipigon's development partner Leaderna Therapeutics reports last person treated in ongoing Phase 1 study with Lipisense®

Lipigon Pharmaceuticals

Press release8/28/2024, 5:43 AM

Redeye: Lipigon Q2 2024 - Marea Launched

Lipigon Pharmaceuticals

Regulatory press release7/9/2024, 12:00 PM

Lipigon Receives Milestone Payment of USD 1 Million from Leaderna for Approval of Phase I Bridging Study

Lipigon Pharmaceuticals

Press release6/20/2024, 6:30 AM

New Publication: The ANGPTL4 Protein May Reduce the Risk of Cardiovascular Disease and Diabetes

Lipigon Pharmaceuticals

Press release5/29/2024, 6:03 AM

Redeye: Lipigon Q1 2024 - Phase II Underway

Lipigon Pharmaceuticals

Press release5/15/2024, 6:28 AM

Lipigon and Leaderna Collaboration on Lipisense® Shows Good Progress

Lipigon Pharmaceuticals

Regulatory press release5/14/2024, 5:53 AM

Lipigon collaborates with University of Washington on lung damage project

Lipigon Pharmaceuticals

Press release2/23/2024, 7:08 AM

Redeye: Lipigon Q4 2023 - Phase II study approved

Lipigon Pharmaceuticals

Press release2/7/2024, 3:00 PM

The Swedish Medical Products Agency approves Lipigon's phase II study with Lipisense®

Lipigon Pharmaceuticals

Press release12/12/2023, 9:11 AM

Lipisense® progressing to Phase II - what comes next?

Lipigon Pharmaceuticals

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.